

Special Issue

Metformin and Cancer

Message from the Guest Editor

Metformin is the most commonly used antidiabetic drug, with a plethora of proven benefits and an exceptional safety profile. On top of the established metabolic effects, epidemiologic evidence shows that metformin use is associated with decreased cancer risk and/or improved disease prognosis in diabetics on metformin. Metformin primarily targets the liver where it suppresses gluconeogenesis and causes decrease of blood glucose concentration. Other liver-independent metabolic effects (such as gut microbiome) have been documented as well. Mechanisms responsible for metformin's anti-cancer effect have been investigated extensively, focusing mainly on intracellular energetic stress with subsequent changes of metabolism resulting in cytostatic or cytotoxic action. Large clinical experience with metformin in the treatment of diabetes together with findings of numerous ongoing interventional clinical trials with metformin in various types of cancer might provide evidence-based arguments for eventual repurposing metformin as an adjuvant drug in oncology.

Guest Editor

Prof. Dr. Kateřina Kaňková
Faculty of Medicine, Masaryk University, Brno, Czech Republic

Deadline for manuscript submissions

closed (31 January 2022)



Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



mdpi.com/si/70136

Biomolecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomolecules@mdpi.com

[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)





Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)



About the Journal

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Author Benefits

Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)